What is BPC-157 used for?
BPC-157 is used in preclinical research across tissue-repair, wound-healing, gastrointestinal-protection, vascular-signalling, musculoskeletal-soft-tissue-healing, and neural-research contexts. The compound is supplied for laboratory and bench-research applications only — no major regulator has approved it for therapeutic use in humans or animals.
What the research literature says
BPC-157’s research applications span the canonical preclinical literature anchored by the Sikiric-Seiwerth research group’s three decades of work and cross-laboratory replication. The wound-healing literature is consolidated in the Gwyer review (PMID 34267654). The gastrointestinal-protection literature is consolidated in the Sikiric 2024 comprehensive review (PMID 38980576). The musculoskeletal-soft-tissue-healing literature is consolidated in the Cerovecki review (PMID 30915550). The pleiotropic-activity review extends the framework into neural and multi-system contexts (PMID 38675421).
The dominant mechanistic finding driving these applications is engagement of the VEGFR2 receptor on vascular endothelial cells with downstream Akt phosphorylation and endothelial nitric oxide synthase signalling (PMID 27847966). Growth-hormone-receptor up-regulation in tendon-fibroblast culture is the secondary mechanism anchoring the musculoskeletal applications (PMID 21030672).
The published human-cohort literature is comparatively limited and consists of small pilot studies rather than large clinical-trial programs. Research applications operate within the preclinical and bench-research framework rather than the clinical-trial framework — animal-model tissue-repair research, cell-culture mechanism studies, and adjacent preclinical work.
Why this matters in research context
BPC-157’s published research base supports preclinical applications across multiple tissue-repair contexts. Researchers selecting BPC-157 should anchor protocol design to the specific tissue-repair literature most relevant to the experimental question (gastrointestinal, vascular, musculoskeletal, or neural) rather than to broad “healing” framings. The cross-laboratory replication of the canonical VEGFR2 mechanism provides a robust mechanistic anchor across the application breadth.
Related compounds
- BPC-157 10mg — the compound covered by this answer
- Wolverine Stack (BPC-157 + TB-500 blend) — combined-formulation for tissue-repair research
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110(3):774-780. [PMID 21030672]
- Gwyer D et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021;12:627533. [PMID 34267654]
- Cerovecki T et al. Gastric pentadecapeptide body protection compound BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res 2019. [PMID 30915550]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. BPC-157 is sold strictly as a research-grade reagent for laboratory and bench research applications.